RÉSUMÉ
Clonotypic αß T cell responses to cargoes presented by major histocompatibility complex (MHC), MR1, or CD1 proteins underpin adaptive immunity. Those responses are mostly mediated by complementarity-determining region 3 motifs created by quasi-random T cell receptor (TCR) gene rearrangements, with diversity being highest for TCRγδ. Nonetheless, TCRγδ also displays nonclonotypic innate responsiveness following engagement of germline-encoded Vγ-specific residues by butyrophilin (BTN) or BTN-like (BTNL) proteins that uniquely mediate γδ T cell subset selection. We now report that nonclonotypic TCR engagement likewise induces distinct phenotypes in TCRαß+ cells. Specifically, antibodies to germline-encoded human TCRVß motifs consistently activated naïve or memory T cells toward core states distinct from those induced by anti-CD3 or superantigens and from others commonly reported. Those states combined selective proliferation and effector function with activation-induced inhibitory receptors and memory differentiation. Thus, nonclonotypic TCRVß targeting broadens our perspectives on human T cell response modes and might offer ways to induce clinically beneficial phenotypes in defined T cell subsets.
Sujet(s)
Récepteur lymphocytaire T antigène, alpha-bêta , Récepteur lymphocytaire T antigène, gamma-delta , Humains , Récepteur lymphocytaire T antigène, alpha-bêta/génétique , Sous-populations de lymphocytes T , Butyrophilines/génétique , Butyrophilines/métabolisme , Phénotype , ImmunothérapieRÉSUMÉ
Here we consider how high-content flow cytometric methodology at appropriate scale and throughput rapidly provided meaningful biological data in our recent studies of COVID-19, which we discuss in the context of other similar investigations. In our work, high-throughput flow cytometry was instrumental to identify a consensus immune signature in COVID-19 patients, and to investigate the impact of SARS-CoV-2 exposure on patients with either solid or hematological cancers. We provide here some examples of our 'holistic' approach, in which flow cytometry data generated by lymphocyte and myelomonocyte panels were integrated with other analytical metrics, including SARS-CoV-2-specific serum antibody titers, plasma cytokine/chemokine levels, and in-depth clinical annotation. We report how selective differences between T cell subsets were revealed by a newly described flow cytometric TDS assay to distinguish actively cycling T cells in the peripheral blood. By such approaches, our and others' high-content flow cytometry studies collectively identified overt abnormalities and subtle but critical changes that discriminate the immuno-signature of COVID-19 patients from those of healthy donors and patients with non-COVID respiratory infections. Thereby, these studies offered several meaningful biomarkers of COVID-19 severity that have the potential to improve the management of patients and of hospital resources. In sum, flow cytometry provides an important means for rapidly obtaining data that can guide clinical decision-making without requiring highly expensive, sophisticated equipment, and/or "-omics" capabilities. We consider how this approach might be further developed.
Sujet(s)
COVID-19 , Humains , SARS-CoV-2 , Cytométrie en flux , Cytokines , Sous-populations de lymphocytes TRÉSUMÉ
Whereas pathogen-specific T and B cells are a primary focus of interest during infectious disease, we have used COVID-19 to ask whether their emergence comes at a cost of broader B cell and T cell repertoire disruption. We applied a genomic DNA-based approach to concurrently study the immunoglobulin-heavy (IGH) and T cell receptor (TCR) ß and δ chain loci of 95 individuals. Our approach detected anticipated repertoire focusing for the IGH repertoire, including expansions of clusters of related sequences temporally aligned with SARS-CoV-2-specific seroconversion, and enrichment of some shared SARS-CoV-2-associated sequences. No significant age-related or disease severity-related deficiencies were noted for the IGH repertoire. By contrast, whereas focusing occurred at the TCRß and TCRδ loci, including some TCRß sequence-sharing, disruptive repertoire narrowing was almost entirely limited to many patients aged older than 50 y. By temporarily reducing T cell diversity and by risking expansions of nonbeneficial T cells, these traits may constitute an age-related risk factor for COVID-19, including a vulnerability to new variants for which T cells may provide key protection.
Sujet(s)
Immunité acquise , COVID-19 , Chaines lourdes des immunoglobulines , Récepteur lymphocytaire T antigène, alpha-bêta , Récepteurs aux antigènes des cellules T , SARS-CoV-2 , Immunité acquise/génétique , Sujet âgé , Lymphocytes B/immunologie , COVID-19/génétique , COVID-19/immunologie , Locus génétiques , Humains , Chaines lourdes des immunoglobulines/génétique , Récepteurs aux antigènes des cellules T/génétique , Récepteur lymphocytaire T antigène, alpha-bêta/génétique , SARS-CoV-2/immunologie , Séroconversion , Lymphocytes T/immunologieRÉSUMÉ
BACKGROUND: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer-BioNTech) vaccine in patients with cancer. METHODS: For this prospective observational study, we recruited patients with cancer and healthy controls (mostly health-care workers) from three London hospitals between Dec 8, 2020, and Feb 18, 2021. Participants who were vaccinated between Dec 8 and Dec 29, 2020, received two 30 µg doses of BNT162b2 administered intramuscularly 21 days apart; patients vaccinated after this date received only one 30 µg dose with a planned follow-up boost at 12 weeks. Blood samples were taken before vaccination and at 3 weeks and 5 weeks after the first vaccination. Where possible, serial nasopharyngeal real-time RT-PCR (rRT-PCR) swab tests were done every 10 days or in cases of symptomatic COVID-19. The coprimary endpoints were seroconversion to SARS-CoV-2 spike (S) protein in patients with cancer following the first vaccination with the BNT162b2 vaccine and the effect of vaccine boosting after 21 days on seroconversion. All participants with available data were included in the safety and immunogenicity analyses. Ongoing follow-up is underway for further blood sampling after the delayed (12-week) vaccine boost. This study is registered with the NHS Health Research Authority and Health and Care Research Wales (REC ID 20/HRA/2031). FINDINGS: 151 patients with cancer (95 patients with solid cancer and 56 patients with haematological cancer) and 54 healthy controls were enrolled. For this interim data analysis of the safety and immunogenicity of vaccinated patients with cancer, samples and data obtained up to March 19, 2021, were analysed. After exclusion of 17 patients who had been exposed to SARS-CoV-2 (detected by either antibody seroconversion or a positive rRT-PCR COVID-19 swab test) from the immunogenicity analysis, the proportion of positive anti-S IgG titres at approximately 21 days following a single vaccine inoculum across the three cohorts were 32 (94%; 95% CI 81-98) of 34 healthy controls; 21 (38%; 26-51) of 56 patients with solid cancer, and eight (18%; 10-32) of 44 patients with haematological cancer. 16 healthy controls, 25 patients with solid cancer, and six patients with haematological cancer received a second dose on day 21. Of the patients with available blood samples 2 weeks following a 21-day vaccine boost, and excluding 17 participants with evidence of previous natural SARS-CoV-2 exposure, 18 (95%; 95% CI 75-99) of 19 patients with solid cancer, 12 (100%; 76-100) of 12 healthy controls, and three (60%; 23-88) of five patients with haematological cancers were seropositive, compared with ten (30%; 17-47) of 33, 18 (86%; 65-95) of 21, and four (11%; 4-25) of 36, respectively, who did not receive a boost. The vaccine was well tolerated; no toxicities were reported in 75 (54%) of 140 patients with cancer following the first dose of BNT162b2, and in 22 (71%) of 31 patients with cancer following the second dose. Similarly, no toxicities were reported in 15 (38%) of 40 healthy controls after the first dose and in five (31%) of 16 after the second dose. Injection-site pain within 7 days following the first dose was the most commonly reported local reaction (23 [35%] of 65 patients with cancer; 12 [48%] of 25 healthy controls). No vaccine-related deaths were reported. INTERPRETATION: In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine. FUNDING: King's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute.
Sujet(s)
Vaccins contre la COVID-19/usage thérapeutique , COVID-19/immunologie , Tumeurs/immunologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Anticorps antiviraux/sang , Vaccin BNT162 , COVID-19/sang , COVID-19/complications , COVID-19/virologie , Vaccins contre la COVID-19/immunologie , Relation dose-réponse (immunologie) , Femelle , Humains , Immunogénicité des vaccins/immunologie , Londres/épidémiologie , Mâle , Adulte d'âge moyen , Tumeurs/sang , Tumeurs/complications , Tumeurs/virologie , Études prospectives , SARS-CoV-2 , Pays de GallesRÉSUMÉ
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
Sujet(s)
COVID-19/immunologie , Tumeurs/immunologie , Tumeurs/virologie , Syndrome respiratoire aigu sévère/immunologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , COVID-19/étiologie , COVID-19/mortalité , Femelle , Tumeurs hématologiques/immunologie , Tumeurs hématologiques/mortalité , Tumeurs hématologiques/thérapie , Tumeurs hématologiques/virologie , Humains , Immunophénotypage , Mâle , Adulte d'âge moyen , Partie nasale du pharynx/virologie , Tumeurs/mortalité , Tumeurs/thérapie , Syndrome respiratoire aigu sévère/étiologie , Syndrome respiratoire aigu sévère/mortalité , Syndrome respiratoire aigu sévère/virologie , Lymphocytes T/virologie , Excrétion virale , Jeune adulteRÉSUMÉ
A Correction to this paper has been published: https://doi.org/10.1038/s41591-020-01186-5.
RÉSUMÉ
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
RÉSUMÉ
Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.
Sujet(s)
Anticorps antiviraux/immunologie , Lymphocytes B/immunologie , Infections à coronavirus/immunologie , Cytokines/immunologie , Cellules dendritiques/immunologie , Pneumopathie virale/immunologie , Lymphocytes T/immunologie , Sujet âgé , Sous-populations de lymphocytes B/immunologie , Granulocytes basophiles/immunologie , Betacoronavirus , COVID-19 , Études cas-témoins , Cycle cellulaire , Chimiokine CXCL10/immunologie , Chimiokines/immunologie , Études de cohortes , Infections à coronavirus/sang , Évolution de la maladie , Femelle , Cytométrie en flux , Hospitalisation , Humains , Mémoire immunologique , Immunophénotypage , Interleukine-10/immunologie , Interleukine-6/immunologie , Numération des leucocytes , Activation des lymphocytes/immunologie , Mâle , Adulte d'âge moyen , Pandémies , Pneumopathie virale/sang , Pronostic , SARS-CoV-2 , Indice de gravité de la maladie , Sous-populations de lymphocytes T/immunologie , Régulation positiveRÉSUMÉ
The important role of the local mucosal environment in both the initiation and progression of allergic disease is well established. Analysis of tissue-resident lymphocyte subsets by flow cytometry requires isolation of viable cells from mucosal samples.Here we describe an advanced method to dissociate lymphocytes from human mucosal (e.g., nasal, bronchial) biopsies. Single-cell suspensions are obtained through a combination of gentle mechanical disruption and incubation of tissue with proteolytic enzymes. This method fully utilizes limited clinical samples and is amenable to a variety of downstream applications for phenotypic, single-cell analysis of tissue lymphocytes or pooled lymphocyte subsets.